Glioblastoma's notorious resistance to treatment may finally have a biochemical explanation that opens new therapeutic doors. This deadliest brain cancer kills most patients within 15 months partly because its stem cells develop clever workarounds to radiation therapy, the current standard of care.
The culprit appears to be a metabolic hijacking system where two enzymes work in tandem to fuel DNA repair. When radiation damages glioblastoma stem cells, the ATM protein activates phosphoglycerate kinase 1 (PGK1), which then phosphorylates phosphoglycerate dehydrogenase (PHGDH) at a specific threonine residue. This phosphorylation dramatically increases PHGDH's ability to produce serine, an amino acid that becomes the raw material for S-adenosylmethionine synthesis. The resulting surge in cellular methylation capacity enhances histone modifications that recruit RAD51 proteins, creating a highly efficient homologous recombination repair system that essentially patches up radiation damage.
This discovery illuminates why serine synthesis pathways have emerged as cancer metabolism targets across multiple tumor types. Unlike normal cells that can import serine from circulation, rapidly dividing cancer cells often require autonomous serine production to meet their biosynthetic demands. The finding that PHGDH enzymatic inhibition sensitizes glioblastoma stem cells to radiation suggests combination approaches could overcome treatment resistance.
Clinical validation strengthens these mechanistic insights - patients showing higher phosphorylation levels of both enzymes experienced significantly worse outcomes. However, this represents early-stage research requiring extensive validation before clinical translation. The challenge lies in selectively targeting this pathway in cancer cells while preserving normal brain cell function, given serine's essential role in cellular metabolism.